samedan logo
 
 
 
spacer
home > pmps > summer 2018 > the race to market
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Race to Market

The development of a new drug product therapy is a complex process that requires careful planning and meticulous execution. Even with these prerequisites, it can result in long lead times, high costs, and immense risks, with development timelines often exceeding 10 years from discovery to regulatory approval. For combination products, the process of bringing a product to market is complicated further. With growing competition in the market of injectable products, drug delivery systems have become increasingly important for the patient, caregiver, and healthcare professionals in terms of ease of use as well as product differentiation. These factors require pharmaceutical and biotechnology companies to identify a strategy for a drug delivery system early in the drug development phase to effectively and efficiently bring the combination product to market.

As the expert that understands the intricacies of the self-injection process and the complexities of the combination product development timelines, a device developer is often contracted to help companies maximise investments and minimise potential delays to commercial launch. Combining this knowledge and experience with a strong set of in-house capabilities, the development process can often be expedited, ultimately ensuring the successful commercialisation of the combination product in a timely manner.

Of Primary Importance

An auto-injector consists of a drugcontaining primary container and a device containing many moving parts and mechanical forces specifically designed to ensure that the drug product is fully injected within the specified delivery requirements. Both the drug product and device are highly regulated components, and the efforts to deliver the drug safely and effectively is an undertaking that requires close collaboration between the company and the device developer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Taras Seniuch is Director of Business Development at SHL Group: designer, developer, and manufacturer of advanced drug delivery devices such as auto-injectors and pen injectors. With over 17 years of experience within the pharma and medical device industry, Taras leads the business development efforts for the CMO, SHL Pharma, which provides assembly and secondary packaging solutions for SHL-designed devices for pharma and biotech products.
spacer
Taras Seniuch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement